Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 8/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1183588 | 1.00 | L3MBTL1 (0.48) | L3MBTL1MAPTLMNATP53THRB | |
| SCHEMBL1184318 | 0.88 | ALDH1A1 (0.47) | MAPTLMNATHRBSMN1; SMN2ALDH1A1 | |
| SCHEMBL1183684 | 0.88 | ALDH1A1 (0.47) | MAPTLMNATHRBSMN1; SMN2ALDH1A1 | |
| SCHEMBL1182601 | 0.87 | L3MBTL1 (0.51) | L3MBTL1MAPTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL1183552 | 0.87 | L3MBTL1 (0.51) | L3MBTL1MAPTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL20521472 | 0.82 | NPSR1 (0.43) | L3MBTL1MAPTLMNATP53THRB | |
| SCHEMBL1183542 | 0.82 | GPR119 (0.55) | MAPTLMNASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL22532774 | 0.82 | SMN1; SMN2 (0.56) | L3MBTL1MAPTLMNATP53THRB | |
| SCHEMBL1183417 | 0.82 | GPR119 (0.55) | MAPTLMNASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL1183293 | 0.82 | GPR119 (0.55) | MAPTLMNASMN1; SMN2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059969-A1 | PIPERAZINES AS ANTI-OBESITY AGENTS | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | disclosed |
| US-20110046135-A1 | NEW COMPOUNDS I | ASTRAZENECA AB (PUBL) (SE) | 2011-02-24 | — | — | US | disclosed |
| US-7851471-B2 | Compounds I | ASTRAZENECA AB (PUBL) (SE) | 2010-12-14 | — | — | US | disclosed |
| EP-2229362-A1 | PIPERAZINES AS ANTI-OBESITY AGENTS | AstraZeneca AB (SE) | 2010-09-22 | — | — | EP | disclosed |
| US-20090181967-A1 | New compounds I | BIOVITRUM AB (SE) | 2009-07-16 | — | — | US | disclosed |
| WO-2009071658-A1 | PIPERAZINES AS ANTI-OBESITY AGENTS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181967-A1 | New compounds I | GPR119, GLP1R, FABP4 | L3MBTL1 4605/4885MAPT 4536/4885LMNA 1076/4885 |
| US-20110046135-A1 | NEW COMPOUNDS I | GPR119, GLP1R, FABP4 | L3MBTL1 4605/4885MAPT 4536/4885LMNA 1076/4885 |
| US-20110059969-A1 | PIPERAZINES AS ANTI-OBESITY AGENTS | GPR119, FABP4, ADIPOR2 | L3MBTL1 4663/4885MAPT 4640/4885LMNA 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.